Abstract: The present invention relates to novel peptides and derivatives thereof useful as selective ?1-adrenoceptor antagonists which ability of inhibiting the agonist action of agonist noradrenaline on the ?1-adrenoceptor is greater than their ability of inhibiting the action of agonist noradrenaline on the other ?-adrenoceptors. The invention also relates to pharmaceutical compositions comprising these peptides.

Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Abstract: The invention relates to an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.

Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and/or TNF&agr;-mediated diseases including degenerative diseases and certain cancers.

Abstract: A flow connector comprises first and second flowpath components engageable in an engagement direction. The first and second components have respective ports defining a flow path therebetween. The connector further comprises a sealing member moveable in the engagement direction between a first position between said ports and in said flow path, in which flow between said ports is prevented, and a second position not between said ports and out of said flow path, in which flow between said ports is permitted.

Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Abstract: Quinolone derivatives of formula (1) are described: 1

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives.

Abstract: The invention relates to hydroxamic and carboxylic acid derivatives. Compounds of the formula: are disclosed. These compounds are useful for the treatment of diseases mediated by inhibitors of matrix metalloproteinase, ADAM, ADAM-TS enzymes, and or INF&agr;-mediated diseases including degenerative diseases and certain cancers.

Abstract: A compound of the formula wherein R1 is C1-3 alkyl optionally substituted with one or more fluorines; R2 is C1-6 alkyl, cycloalkyl or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, each represents C1-3 alkyl, halogen, CF3 or CN; or a pharmaceutically-acceptable salt thereof.

Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.

Abstract: A pharmacologically active compound of formula (I) 1

Abstract: Compounds that are inhibitors of phosphodiesterase and have therapeutic utility, are of formula (i) wherein R1 is C3-6 cycoalkyl, or C1-3 alkyl optionally substituted with one or more fluorine atoms; R2 is C1-6 alkyl, C3-6 cycloalkyl, CF3, CH2CF3, C2F5 or NR4R5; R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C) NR4R5 is a nitrogen-containing heterocyclic ring; R6 is C1-3 alkyl; and R7 and R8, which are the same or different, are each H, C1-3 alkyl, halogen, CF3 or CN, provided that both are not H; or a pharmaceutically-acceptable salt thereof

Abstract: A shape modulation transmit loop with digital frequency control permits spectral shaping of a digital pulse stream (12) by controlling the slew rate of the transition signal (16) between successive pulses. The loop is formed when the digital data stream is fed into an up/down counter (152) whose output is coupled to a programmable memory means (154), such as RAM, EEPROM, flash memory or similar electronic storage means. The output (108) of the programmable memory (154) forms a first input to an adder (112) which drives an accumulator (52) with specified steps. Values corresponding to the desired waveform (70) are stored in a lookup table (60) which is coupled to a digital-to-analog conversion circuit (64) which uses the values in the lookup table (60) to construct a sine wave output signal (70) corresponding to the frequency set by the current specified step of the up/down counter (152).

Abstract: The compound, according to formula (i) wherein X and Y are independently CH, N or N-oxide, provided that X and Y do not both represent CH; Z is CO or CS; R1 is alkyl, optionally substituted with one or more halogens; and R2, R3, R4 and R5 are each various organic groups. Such compounds have therapeutic utility, via inhibition of phosphodiesterase IV.

Abstract: A compound of formula (i) ##STR1## has therapeutic utility via inhibition of phosphodiesterase and THF release.

Abstract: A demodulator (200) including a phase detector (201) receiving a modulated signal and outputting a demodulated signal. The phase detector (201) also receives a reference signal. A programmable voltage circuit (203, 204) outputs an analog voltage. A reference signal generator (208) that is responsive to the programmable voltage circuit (204) and the demodulated signal has an output coupled to provide the reference signal to the phase detector (201). A window detect circuit (206) with an input coupled to the demodulated signal generates an inhibit signal when the demodulated signal is within preselected limits. The inhibit signal is coupled to latch the programmable voltage circuit (203, 204). Preferably, the programmable voltage circuit is implemented as a digital-to-analog converter (204) driven by a counter (203) or by a processor circuit (302).